ProMIS Neurosciences (PMN, Financial) received attention from HC Wainwright & Co., as the firm initiated coverage on the biotechnology company. The announcement was made on July 14, 2025.
HC Wainwright & Co. analyst Raghuram Selvaraju gave ProMIS Neurosciences (PMN, Financial) a "Buy" rating, setting the current price target at USD 4.00. This marks a new coverage for PMN by the analyst, as there were no previous ratings or price targets listed.
This initiation places ProMIS Neurosciences (PMN, Financial) under the spotlight for investors, as the "Buy" rating suggests a positive outlook for the company's stock performance.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 3 analysts, the average target price for ProMIS Neurosciences Inc (PMN, Financial) is $5.67 with a high estimate of $8.00 and a low estimate of $3.00. The average target implies an upside of 1,351.50% from the current price of $0.39. More detailed estimate data can be found on the ProMIS Neurosciences Inc (PMN) Forecast page.
Based on the consensus recommendation from 3 brokerage firms, ProMIS Neurosciences Inc's (PMN, Financial) average brokerage recommendation is currently 1.3, indicating "Buy" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
